Liraglutide Dosage Guide

Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist developed by Novo Nordisk and first approved by the FDA in 2010. It is a synthetic analog of human GLP-1 with 97% amino acid sequence homology to the native incretin hormone. A C-16 palmitoyl fatty acid side chain is attached at position 26 via a glutamic acid spacer, enabling the molecule to bind to albumin in the bloodstream. This albumin binding extends the half-life from ~2 minutes (native GLP-1) to approximately 13 hours — making Liraglutide the first GLP-1 receptor agonist suitable for once-daily injection.

Liraglutide is marketed under two brand names: Victoza (FDA-approved for type 2 diabetes, maximum 1.8 mg/day) and Saxenda (FDA-approved for chronic weight management, maximum 3.0 mg/day). Its mechanism of action includes slowing gastric emptying, reducing appetite through hypothalamic signaling, enhancing glucose-dependent insulin secretion, and suppressing glucagon release. The landmark LEADER trial (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results) demonstrated a 13% reduction in major adverse cardiovascular events (MACE) and a 22% reduction in cardiovascular death in patients with type 2 diabetes.

Use our Peptide Dosage to calculate your exact dose based on vial size and concentration.

For a complete overview of its mechanism and research, see our full Liraglutide profile. For a comparison with weekly GLP-1 agonists, see our Semaglutide Dosage Guide. New to peptides? Start with the Beginner's Guide to Peptides.

Liraglutide requires a structured, stepwise dose titration. The schedules below are the FDA-approved titration protocols from the official prescribing information. Never skip titration steps — the 0.6 mg starting dose is NOT therapeutic and exists exclusively for GI adaptation.

Saxenda Titration (Weight Management — 3.0 mg Target)

Victoza Titration (Type 2 Diabetes — 1.2–1.8 mg Target)

Handling GI Intolerance During Titration

• If nausea is severe at a given dose: Stay at that dose for an additional week before escalating. The standard schedule is a minimum recommendation — extending titration steps is acceptable.
• If GI side effects remain intolerable: Step back to the previous tolerated dose for 1–2 weeks, then re-attempt escalation.
• Supportive measures: Eat smaller, more frequent meals; avoid high-fat foods; stay well-hydrated; consider ginger or ondansetron for nausea if medically appropriate.

Discontinuation Criteria

Per the Saxenda prescribing information: if a patient has not lost at least 4% of body weight by 16 weeks at the 3.0 mg dose, Liraglutide should be discontinued, as continued use is unlikely to produce clinically meaningful weight loss.

Branded pens (Victoza/Saxenda) have built-in dose dials — no calculation is needed. For compounded Liraglutide supplied as lyophilized powder, you need to calculate the injection volume based on your reconstitution concentration.

Quick Reference — 9 mg Vial (3 mL BAC Water)

Quick Reference — 18 mg Vial (3 mL BAC Water)

While the core mechanism — GLP-1 receptor activation — is consistent across applications, the optimal dose and monitoring differ by clinical goal.

Weight Management (Saxenda Protocol)

The primary weight loss indication. Liraglutide 3.0 mg daily suppresses appetite, slows gastric emptying, and enhances satiety signaling. The SCALE trials demonstrated 8.0% mean body weight loss over 56 weeks, with approximately one-third of patients achieving ≥10% weight loss.

• Target dose: 3.0 mg daily (SubQ)
• Titration: 5-week escalation starting at 0.6 mg
• Assessment: Evaluate at 16 weeks — discontinue if <4% body weight loss
• Duration: Long-term use; weight regain is common after discontinuation
• Adjuncts: Reduced-calorie diet and increased physical activity are essential for optimal results

Type 2 Diabetes (Victoza Protocol)

Liraglutide 1.2–1.8 mg daily improves glycemic control by enhancing glucose-dependent insulin secretion, suppressing glucagon, and slowing gastric emptying. The LEAD trials demonstrated HbA1c reductions of 0.8–1.5%.

• Target dose: 1.2 mg daily; increase to 1.8 mg if glycemic control is inadequate
• Titration: 1 week at 0.6 mg, then escalate to 1.2 mg
• Monitoring: HbA1c, fasting glucose, post-prandial glucose
• Combination therapy: Often used with metformin, sulfonylureas, or basal insulin (adjust insulin/SU doses to reduce hypoglycemia risk)

Cardiovascular Risk Reduction

Based on the LEADER trial, Liraglutide 1.8 mg daily demonstrated significant cardiovascular benefit in patients with type 2 diabetes and established cardiovascular disease or high CV risk. This indication specifically applies to T2D patients with existing cardiovascular concerns.

• Target dose: 1.8 mg daily (SubQ)
• Population: T2D patients with established CVD or multiple CV risk factors
• Outcome data: 13% MACE reduction, 22% CV death reduction (LEADER trial)
• Duration: Long-term / indefinite with ongoing monitoring

General Metabolic Health (Lower Dose)

Some practitioners prescribe Liraglutide at lower doses (1.2–1.8 mg) for patients seeking metabolic optimization — improved insulin sensitivity, modest weight loss, and appetite regulation — without a formal diabetes or obesity diagnosis. This is an off-label use.

• Target dose: 1.2–1.8 mg daily (SubQ)
• Titration: Standard 0.6 mg start, escalate weekly
• Monitoring: Fasting glucose, fasting insulin, HbA1c, lipid panel, body weight
• Notes: Lower doses produce fewer GI side effects and may be sufficient for patients with milder metabolic dysfunction

Liraglutide therapy follows a predictable pattern of titration, adaptation, and therapeutic effect. Understanding the timeline helps set realistic expectations and manage side effects.

Long-Term Duration

• Weight management: Liraglutide is approved for long-term use. Weight regain is common after discontinuation, so indefinite therapy may be necessary to maintain weight loss.
• Type 2 diabetes: Used as long-term maintenance therapy. The LEADER trial followed patients for a median of 3.8 years with continued benefit.
• Discontinuation: If stopping Liraglutide, consider a gradual taper (reversing the titration schedule) over 2–4 weeks to minimize appetite rebound and GI adjustment.

Very Common Side Effects (≥10% Incidence)

Data from the SCALE clinical program (Liraglutide 3.0 mg for weight management):

• Nausea — 39.3% (vs 13.8% placebo). Most common side effect; typically peaks during weeks 3–4 and subsides by weeks 8–12
• Diarrhea — 20.9% (vs 9.9% placebo)
• Constipation — 19.4% (vs 8.5% placebo)
• Vomiting — 15.7% (vs 3.9% placebo)
• Decreased appetite — 10.0% (this is also the intended therapeutic effect)

Common Side Effects (1–10% Incidence)

• Headache, dizziness, fatigue
• Dyspepsia (indigestion), abdominal pain
• Injection site reactions (redness, pain, itching)
• Hypoglycemia (primarily when combined with insulin or sulfonylureas)
• Increased heart rate (mean increase 2–3 bpm in clinical trials)

Serious Side Effects (Rare but Important)

• Pancreatitis — acute pancreatitis has been reported. Discontinue immediately if severe, persistent abdominal pain occurs (especially radiating to the back). Monitor amylase and lipase levels.
• Gallbladder disease — cholelithiasis (gallstones) and cholecystitis have been reported at higher rates in clinical trials, likely related to rapid weight loss.
• Acute kidney injury — reported in association with severe nausea, vomiting, and diarrhea causing dehydration. Maintain adequate hydration, especially during titration.
• Suicidal ideation — post-marketing reports. Monitor for changes in mood or behavior. Discuss mental health history with your prescriber before starting.
• Thyroid C-cell tumors — observed in rodent studies (see black box warning above). Clinical significance in humans is unknown.

Contraindications

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• History of pancreatitis — use with extreme caution; generally contraindicated
• Pregnancy — Category X. Discontinue at least 2 months before a planned pregnancy
• Breastfeeding — not recommended; unknown whether Liraglutide passes into breast milk
• Type 1 diabetes — Liraglutide is not indicated for and should not be used in type 1 diabetes or diabetic ketoacidosis
• Known hypersensitivity to Liraglutide or any formulation excipient

Drug Interactions

• Insulin and sulfonylureas: Liraglutide enhances insulin secretion. When added to insulin or sulfonylurea therapy, the risk of hypoglycemia increases. Consider reducing insulin/SU doses when initiating Liraglutide.
• Oral medications (general): Liraglutide slows gastric emptying, which may delay absorption of oral medications. Take time-sensitive oral medications (e.g., antibiotics, oral contraceptives) at least 1 hour before or 4 hours after Liraglutide, or as directed.
• Warfarin: Liraglutide may affect warfarin absorption. Monitor INR more frequently when initiating or changing Liraglutide doses in patients on warfarin.

Recommended Monitoring

• Baseline and periodic: HbA1c, fasting glucose, lipid panel, renal function (BUN/creatinine), amylase/lipase, thyroid function
• Body weight: Track weekly during titration, monthly during maintenance
• Heart rate: Liraglutide increases resting heart rate by 2–3 bpm on average
• Signs of pancreatitis: Severe, persistent abdominal pain
• Signs of gallbladder disease: Right upper quadrant pain, especially after meals